Development of Adamantane-based hydrophobic tags targeting anaplastic lymphoma kinase with enhanced antitumor...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Anaplastic Lymphoma Kinase (ALK) is a key target in cancers like non-small cell lung cancer (NSCLC) and anaplastic large-cell lymphomas (ALCLs).
• Developing targeted therapies to degrade ALK is crucial for effective cancer treatment.

Purpose of the Study:

• To design and synthesize novel ALK-targeting degraders using the hydrophobic tagging (HyT) strategy.
• To evaluate the efficacy and mechanism of action of these novel ALK degraders.

Main Methods:

• Utilized the hydrophobic tagging (HyT) strategy to link an ALK inhibitor derivative (A3) to adamantane via customized linkers.
• Synthesized and tested a series of novel ALK degraders, with a focus on compound H7.
• Assessed ALK degradation, anti-proliferative effects, and cytotoxicity in ALK-dependent and independent cell lines.
• Investigated the mechanism of degradation, including the role of the ubiquitin-proteasome system and chaperones.

Main Results:

• Compound H7 demonstrated potent ALK degradation activity both in vitro and in vivo.
• H7 exhibited significant anti-proliferative effects in ALK-dependent cancer cell lines.
• Minimal cytotoxicity was observed in cells lacking ALK fusion proteins, indicating target specificity.
• The degradation process mediated by H7 involves the ubiquitin-proteasome system and requires chaperones.

Conclusions:

• The novel HyT-based ALK degraders, particularly H7, show significant therapeutic potential for ALK-related malignancies.
• Compound H7 effectively targets and degrades ALK through the ubiquitin-proteasome pathway.
• These findings pave the way for developing advanced ALK-targeting therapies for various cancers.